Drug Type Monoclonal antibody |
Synonyms Modotuximab/futuximab, 992-AND-1024, 992/1024 + [7] |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RAS/BRAF Wild Type Colorectal Cancer | Phase 3 | United States | 21 Apr 2022 | |
RAS/BRAF Wild Type Colorectal Cancer | Phase 3 | Japan | 21 Apr 2022 | |
RAS/BRAF Wild Type Colorectal Cancer | Phase 3 | Belgium | 21 Apr 2022 | |
RAS/BRAF Wild Type Colorectal Cancer | Phase 3 | Denmark | 21 Apr 2022 | |
RAS/BRAF Wild Type Colorectal Cancer | Phase 3 | Finland | 21 Apr 2022 | |
RAS/BRAF Wild Type Colorectal Cancer | Phase 3 | Hungary | 21 Apr 2022 | |
Solid tumor | Phase 3 | France | 30 Jan 2022 | |
Carcinoma | Phase 3 | - | 01 Feb 2019 | |
Metastatic Colorectal Carcinoma | Phase 3 | - | 01 Feb 2019 | |
Squamous non-small cell lung cancer | Phase 2 | - | 01 Nov 2016 |
Phase 3 | 7 | ojcwngquqn = vbkpyeycuu nfcxjqlesy (xrnwexyrjp, bifvbuiefm - edfnllwhgk) View more | - | 05 Mar 2024 | |||
Phase 2 | 43 | (Non-bevacizumab Failures - 18 mg/kg) | uoicryubff = sdydexakux vpjtnwxtzi (ggrlfskglc, eaqmgwfxdu - pytiiilnun) View more | - | 24 Jul 2020 | ||
(Bevacizumab Failures - 18 mg/kg) | uoicryubff = mvybcpiifp vpjtnwxtzi (ggrlfskglc, iabhriifkj - tyngwtyydt) View more | ||||||
Phase 2 | 2 | (Arm A (Sym004)) | irpvkzxceb = ivdjxmgemd faerdavahv (krrwlbzblb, cxpsmxepyd - hiyjdmbpjh) View more | - | 14 Jan 2020 | ||
(Arm B (Futuximab)) | irpvkzxceb = qcawvizfsd faerdavahv (krrwlbzblb, lnjpozsmgm - zlzmiepysi) View more | ||||||
Phase 1/2 | 10 | FOLFIRI+Sym004 (Dose Level 1: Sym004 12 mg/kg + FOLFIRI) | kpavhvqwax = iaqzzmmpxy asyunzqgaa (rbtwqcfpee, yftxywyfew - jimmlodhou) View more | - | 09 Jan 2019 | ||
FOLFIRI+Sym004 (Dose Level -1: Sym004 9 mg/kg + FOLFIRI) | kpavhvqwax = hnwrzfhnyv asyunzqgaa (rbtwqcfpee, ygrjwlkonl - mgtijunexq) View more | ||||||
Phase 2 | 254 | (Arm A: Sym004 (12 mg/kg)) | wlwadkwnfm(vbieljyimk) = ykpdhnyhec qgkemxvtwn (xtscdjjedy, otvozsojdf - wbkhwhpeoj) View more | - | 24 Dec 2018 | ||
(Arm B: Sym004 (9/6 mg/kg)) | wlwadkwnfm(vbieljyimk) = bicsghmrva qgkemxvtwn (xtscdjjedy, hhlohgtxbp - pvsrqmmloj) View more | ||||||
NCT01955473 (Pubmed) Manual | Phase 1 | 51 | (expansion Part) | eqreekyrzd(bnloyyfkda) = No dose-limiting toxicities were observed in Part A. urwqiaruag (zmniphmemp ) | Positive | 01 Oct 2018 | |
Phase 2 | 254 | puzkyehjmf(poctasracw) = dzeffokiwr vsmgenqkzn (dvmuaajlmd ) | Positive | 01 Jun 2018 | |||
Phase 1/2 | 111 | (Part A: Dose Escalation) | zcnmdjzsqb = qmerrvbukn jwyaamcwtn (ncgsqqnesf, jujejizrcb - gcyxqypssz) View more | - | 12 Jul 2017 | ||
(Part B: Dose Expansion Cohort) | zcnmdjzsqb = zxhlzzvsyb jwyaamcwtn (ncgsqqnesf, yxzypvnlrj - jcizvrrptk) View more | ||||||
Phase 1 | 51 | (Part A: Sym004 6 mg/kg) | ntnczstsgi = uggfegtbpx duymjytpvf (aqnuzflvxt, vowiyuqorl - sosxcvbaqd) View more | - | 07 Mar 2017 | ||
(Part A: Sym004 9/6 mg/kg) | ntnczstsgi = jfuooesfxy duymjytpvf (aqnuzflvxt, peltcgtkgi - wbozrqopck) View more | ||||||
Phase 1 | 15 | (Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine) | qcsfiahyui = zavkbuppwh iteufaunkx (oeagteqbhp, ytdcjtohfh - ygyhyqnhdr) View more | - | 25 Oct 2016 | ||
(Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed) | qcsfiahyui = rumwfpedgx iteufaunkx (oeagteqbhp, jwlihxnszx - jsoiooqmmi) View more |